Physician profile
Kathy Jo Cramer
NPI 1831582584
$742.74
in general payments reported to CMS, 2019-2025
11 companies · $78.79 in 2025
The $78.79 reported for 2025 was less than what a typical Psychiatric/Mental Health (Nurse Practitioner) provider received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $13.29 · 2022: $95.47 · 2023: $318 · 2024: $237 · 2025: $78.79.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $634.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $633.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $350.66 | 2021-2025 | |
| Axsome Therapeutics, INC. | $124.25 | 2023-2024 | Auvelity |
| Vanda Pharmaceuticals INC. | $68.81 | 2023-2025 | Fanapt, Hetlioz |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $63.56 | 2022 | |
| Alkermes, INC. | $35.78 | 2022-2023 | Aristada, Lybalvi |
| Indivior INC. | $28.14 | 2023 | Perseris |
| Janssen Pharmaceuticals, INC | $15.76 | 2025 | Invega Sustenna |
| Corium, LLC | $14.55 | 2024 | Azstarys |
| Lundbeck LLC | $14.54 | 2024 | Rexulti |
| Teva Pharmaceuticals USA, INC. | $14.33 | 2025 | Uzedy |
| Sunovion Pharmaceuticals INC. | $12.36 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kathy Cramer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.